Patents Assigned to Medarex
  • Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
    Patent number: 8263073
    Abstract: The present invention provides isolated monoclonal antibodies that bind to CTLA-4 and that are capable of increasing the response of T cells to antigenic stimulation in vivo yet the antibodies do not substantially block the binding of CTLA-4 to B7 ligands (e.g., B7-1 and B7-2) in vitro. Thus, the antibodies of the invention demonstrate that is it possible to separate the immunostimulatory function of anti-CTLA-4 antibodies from their ability to block the binding of B7 ligands. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for increasing the response of T cells to antigenic stimulation using the antibodies of the invention, including methods for treating cancer using the antibodies of the invention.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: September 11, 2012
    Assignee: Medarex, Inc.
    Inventors: Alan Korman, Edward L. Halk, Changyu Wang, Kent B. Thudium, Lan Yang, Kristopher Toy
  • Antibodies against toxins and uses thereof
    Patent number: 8257709
    Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: September 4, 2012
    Assignees: University of Massachusetts, Medarex, Inc.
    Inventors: Donna M. Ambrosino, Gregory J. Babcock, Teresa Broering, Robert Graziano, Hector Javier Hernandez, Israel Lowy, Robert Mandell, Deborah Molrine, William D. Thomas, Jr., Hui-Fen Zhang
  • IP-10 antibodies and their uses
    Patent number: 8258266
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: September 4, 2012
    Assignee: Medarex, Inc.
    Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David B. Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
  • HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND METHODS FOR USING ANTI-PTK7 ANTIBODIES
    Publication number: 20120219557
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.
    Type: Application
    Filed: May 10, 2012
    Publication date: August 30, 2012
    Applicant: MEDAREX, INC.
    Inventors: Jonathan Alexander TERRETT, Li-Sheng LU, Chin PAN
  • Human monoclonal antibodies to BTLA and methods of use
    Patent number: 8247537
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: August 21, 2012
    Assignee: Medarex, Inc.
    Inventors: Alan Korman, Mark Selby, Kent B. Thuduim, Edward Halk, Mohan Srinivasan, David B. Passmore
  • HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND METHODS FOR USING ANTI-PTK7 ANTIBODIES
    Publication number: 20120207764
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.
    Type: Application
    Filed: April 9, 2012
    Publication date: August 16, 2012
    Applicant: MEDAREX, INC.
    Inventors: Jonathan Alexander TERRETT, Li-Sheng LU, Chin PAN
  • Antibodies against clostridium difficile toxins and uses thereof
    Patent number: 8236311
    Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: August 7, 2012
    Assignees: University of Massachusetts, Medarex, Inc.
    Inventors: Donna M. Ambrosino, Gregory J. Babcock, Teresa Broering, Robert Graziano, Hector Javier Hernandez, Israel Lowy, Robert Mandell, Deborah Molrine, William D. Thomas, Jr., Hui-Fen Zhang
  • Therapeutic human anti-IL-1R1 monoclonal antibody
    Patent number: 8236559
    Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: August 7, 2012
    Assignees: Medarex, Inc., Amgen Inc.
    Inventors: Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
  • Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
    Patent number: 8232449
    Abstract: The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: July 31, 2012
    Assignee: Medarex, Inc.
    Inventors: Dawn M. Tanamachi, Peter Brams, Amelia Black
  • FULLY HUMAN ANTIBODIES TO BTLA
    Publication number: 20120183565
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Application
    Filed: July 26, 2010
    Publication date: July 19, 2012
    Applicants: N.V. ORGANON, MEDAREX, INC.
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark Selby, Timothy W. Sproul, Heidi N. Leblanc
  • Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
    Patent number: 8222375
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: July 17, 2012
    Assignee: MEDAREX, Inc.
    Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Chin Pan
  • Monoclonal antibodies against CD30 lacking in fucosyl residues
    Patent number: 8207303
    Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: June 26, 2012
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, Amelia Nancy Black
  • Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors
    Publication number: 20120156725
    Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
    Type: Application
    Filed: January 27, 2012
    Publication date: June 21, 2012
    Applicants: MEDAREX, INC., AMGEN INC.
    Inventors: William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
  • Nucleic acid molecules that encode human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors
    Patent number: 8202976
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: June 19, 2012
    Assignees: Amgen Inc., Medarex, Inc.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng (Luke) Li, Haichun Huang
  • HUMAN MONOCLONAL ANTIBODIES AGAINST BACILLUS ANTHRACIS PROTECTIVE ANTIGEN
    Publication number: 20120114662
    Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: October 7, 2008
    Publication date: May 10, 2012
    Applicant: MEDAREX, INC.
    Inventors: Tibor KELER, Israel LOWY, Laura A. VITALE, Diann BLANSET, Mohan SRINIVASAN
  • FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1
    Publication number: 20120093826
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.
    Type: Application
    Filed: March 5, 2010
    Publication date: April 19, 2012
    Applicants: OXFORD BIOTHERAPEUTICS LTD, MEDAREX, INC.
    Inventors: Jonathan Alexander Terrett, Heidi Leblanc, Haichun Huang, Erika Meaddough, Chin Pan, Bingliang Chen, Chetana Rao-Naik
  • Transgenic non-human animals for producing chimeric antibodies
    Patent number: 8158419
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: April 17, 2012
    Assignee: Medarex, Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Methods of treatment using CTLA-4 antibodies
    Patent number: 8142778
    Abstract: The present invention provides method of treatment using human sequence antibodies against human CTLA-4 linked to a cytotoxic agent. In particular, methods of treating cancer and autoimmune disease are provided.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: March 27, 2012
    Assignee: Medarex, Inc.
    Inventors: Thomas Andrew Davis, Tibor P. Keler, Robert F. Graziano, Alan J. Korman
  • NEUROPILIN-1 INHIBITORS
    Publication number: 20120058117
    Abstract: The present invention relates to molecules interfering with the function of neuropilin-1 in the context of angiogenesis and the treatment of cancer. Molecules, polypeptides, antibodies, compositions and methods are provided that are useful for reducing, inhibiting or treating angiogenesis, the invasion of blood vessels into tumors, and/or the invasion or the metastatic potential of specific tumor cells. Additionally, a method is provided that allows identifying molecules, which interfere with the functionality of neuropilin-1. Furthermore, a method is provided that allows determining whether a naturally occurring tumor cell depends on functional neuropilin-1 for its invasiveness and/or metastatic potential.
    Type: Application
    Filed: June 22, 2011
    Publication date: March 8, 2012
    Applicants: MEDAREX, INC., TUFTS UNIVERSITY
    Inventors: Christine Margarete UNGER, Gerald BESTE, Carolin ZEHETMEIER, Blanca LAIN, Claudia TORELLA, Jens NIEWÖHNER, Daniel G. JAY, Brenda K. EUSTACE, Roland KNAUER, Kristian Hobold JENSEN
  • Protein purification using HCIC and ion exchange chromatography
    Patent number: 8129508
    Abstract: The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity chromatography process without the use of an in-process tangential flow filtration step.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: March 6, 2012
    Assignee: Medarex, Inc.
    Inventors: Alahari Arunakumari, Gisela Maria Marques Ferreira